company overview — achaogen company overview achaogen is a latestage biopharmaceutical company passionately committed to the discovery development and commercialization of innovative antibacterials to treat multidrug resistant mdr gramnegative infectionsthe centers for disease control and prevention cdc characterized carbapenemresistant enterobacteriaceae cre as “nightmare bacteria” and an immediate public health threat that requires “urgent and aggressive action”achaogen is developing plazomicin its lead product candidate for the treatment of serious bacterial infections due to mdr enterobacteriaceae including creachaogen is developing its second product candidate cscape an oral antibacterial that is a combination of an approved betalactam and an approved betalactamase inhibitor with the potential to treat patients with complicated urinary tract infections cuti due to mdr pathogensour research and development pipeline includes additional gramnegative programs such as inhibitors of lpxc an enzyme essential for the synthesis of the outer membrane of many gramnegative bacteria and a therapeutic antibody program  achaogen inc present all rights reserved     privacy policy  terms of use management  achaogen management investor relations investor overview press releases events  presentations corporate governance management board of directors committee composition financials  filings sec filings quarterly results stock information analyst coverage contact us shareholder tools briefcase email alerts snapshot print management board of directors committee composition our executive team has over  years of combined industry experience and a proven track record of leadership global registration and lifecycle management for over  products show all kenneth j hillan mb chb chief executive officer dr hillan joined achaogen in  as chief medical officer and was appointed chief executive officer and a member of its board of directors in october  prior to joining achaogen from august  to april  dr hillan served at genentech inc acquired by roche in  a pharmaceutical company dr hillan was responsible for numerous successful drug approvals and led the medical and scientific strategies for its immunology tissue growth and repair drug portfolio he served in a number of key leadership positions in research and development including senior vice president clinical development inflammation vice president immunology tissue growth and repair itgr vice president development sciences and vice president research operations and pathology dr hillan also previously served as senior vice president and head of clinical development and product development strategy in asiapacific for roche in shanghai china dr hillan currently serves on the board of directors of zymeworks inc and he served on the board of directors of relypsa inc from  until  when it was acquired by galenica ag   dr hillan has an mb chb bachelor of medicine and surgery degree from the faculty of medicine at the university of glasgow uk dr hillan is a fellow of the royal college of surgeons frcs and a fellow of the royal college of pathologists frcpath dr hillan has authored dozens of scientific publications and is a named inventor on almost  issued patents blake wise president and chief operating officer mr wise joined achaogen as chief operating officer in  and in february  he was appointed president and chief operating officer prior to achaogen mr wise spent  years at genentech where he most recently established and led the cross biooncology franchise as vice president cross biooncology in this role mr wise spearheaded crossportfolio oncology initiatives including key account management marketing managed markets companion diagnostics pipeline commercialization and longterm oncology strategy during his time at genentech mr wise also held several other leadership positions of increasing responsibility including senior director franchise head and life cycle leader of the lytics franchise with overall commercial responsibility for genentech’s hospitalbased lytics business he previously served as a sales director in biooncology marketing director in cystic fibrosis and immunology and interactive marketing director where he built genentech’s digital marketing capabilities prior to joining genentech in  mr wise worked in consumer marketing ecommerce and online marketing outside of the healthcare industry in leadership positions at gap inc and webvan mr wise received a bachelor of arts degree in business economics from university of california santa barbara and a masters of business administration degree from university of california berkeley haas school of business janet dorling chief commercial officer ms dorling joined achaogen as chief commercial officer in  prior to achaogen ms dorling spent  years at genentech and roche where as vice president of global product strategy breast cancer at rochegenentech she was responsible for developing and implementing global commercialization and lifecycle strategies for the breast cancer franchise previously as vice president of the lytics franchise ms dorling lead hospitalfocused sales and marketing teams that promoted activase and cathflo in the acute care setting ms dorling also had multiple roles with increasing responsibility in market analysis and strategy in ophthalmology oncology and ultimately leading multiple functions with portfoliowide responsibility prior to joining genentech ms dorling had several roles in business development at altus biologics dna sciences and clontech laboratories ms dorling has a bachelor of arts in molecular and cellular biology from the university of california at berkeley a masters in science in pharmacology and cancer biology from duke university and a masters in business administration from the haas school of business at the university of california at berkeley gary loeb general counsel mr loeb joined achaogen in  after more than  years of legal affairs experience related to intellectual property corporate governance compliance and business development in the biotechnology industry most recently mr loeb has been general counsel and corporate secretary and on the executive team at three life sciences companies amyris inc counsyl and most recently sano intelligence previously mr loeb spent eleven years at genentech most recently as vice president intellectual property where he oversaw  employees in the areas of litigation patent prosecution corporate records and technology licensing    since  mr loeb has been an adjunct professor at university of san francisco law school he is currently on the board of directors for project open hand a nonprofit organization that provides meals to critically ill neighbors and seniors and columbia law school mr loeb received a bachelor of science degree in biology and bachelor of arts degree in english from stanford university in california and a juris doctor degree from columbia law school in new york he clerked in the northern district of texas and for several years practiced commercial and intellectual property law in los angeles and san francisco california   zeryn sarpangal senior vice president of corporate and people strategy ms sarpangal joined achaogen in  and is our senior vice president of corporate and people strategy she has previously served as achaogen’s vice president of human resources and corporate affairs and prior to that as sr director of finance  operations and director of strategic marketing ms sarpangal has prior experience as the vice president of finance  operations at identified an hr data analytics company an engagement manager at mckinsey  company a global management consulting firm and a healthcare investment banking analyst at goldman sachs  co she received a bachelors of arts in economics and molecular  cell biology from university of california berkeley and a masters of business administration from the stanford graduate school of business tobin schilke chief financial officer mr schilke joined achaogen in  after  years at rochegenentech a leading biotechnology company that discovers develops manufactures and commercializes medicines to treat patients with serious or lifethreatening medical conditions he most recently was the cfo and company director of roche products limited in the united kingdom in this role mr schilke was responsible for financial planning and analysis fpa accounting legal  financial compliance supply chain procurement and site services for roche’s pharma presence in the uk previously mr schilke had overall fpa responsibility for genentechs commercial biooncology business and prior to genentech led a number of successful acquisition and spinout deals as a member of the roche corporate ma team prior to joining rochegenentech in  mr schilke was a chemical process development engineer at monsantopharmacia   mr schilke received a bachelor of science degree in chemical engineering from lafayette college in easton pennsylvania a masters of science degree from university of california in berkeley california and a masters of business administration degree from cornell university’s johnson graduate school of management in ithaca new york   lee swem phd chief scientific officer dr swem was appointed chief scientific officer in february  and prior to that was the vice president head of research at achaogen since  prior to this position dr swem spent just under two years as the director of achaogen’s therapeutic antibody program where he developed a stateoftheart antibody discovery platform to rapidly identify rare functional antibodies to treat serious human infectious diseases before joining achaogen dr swem spent approximately four years as a scientist in the department of infectious disease at genentech during his tenure at genentech he developed the antiinfluenza a program the antiinfluenza b program and began a small molecule antibacterial program under his leadership the antiinfluenza teams established an innovative human b cell enrichment and cloning technique to discover rare functional antibodies this work led to the discovery of two broadly neutralizing antibodies targeting influenza a  and influenza bdr swem served as the research lead on the antiinfluenza development teams which successfully transitioned the antiinfluenza a antibody  through phase  and phase  clinical trials and the antiinfluenza b antibody into early development the combination of these two human antibodies could constitute a therapy to treat all serious influenza infections prior to working at genentech dr swem completed his postdoctoral work with dr bonnie bassler at princeton university where he successfully carried out multiple highthroughput screens to identify small molecule inhibitors of bacterial virulence cascades dr swem received his phd in microbiology from indiana university  achaogen inc present all rights reserved     privacy policy  terms of use achaogen home deep experience in antibacterial drug development passionately committed to the discovery development and commercialization of innovative antibacterials to treat multidrug resistant mdr gramnegative infectionspipelinewe are a latestage biopharmaceutical company committed to treating serious infections learn more about our pipelinesciencewe are focused on the discovery and development of antibiotics to treat gramnegative infections and have developed proprietary knowhow through our work on multiple antibiotic classes learn more about our science news  achaogen inc present all rights reserved     privacy policy  terms of use achaogen inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report achaogen inc  product pipeline review   published by global markets direct product code  published september   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license achaogen inc  product pipeline review   published september   content info  pages description summary global markets directs achaogen inc  product pipeline review   provides an overview of the achaogen incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of achaogen incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of achaogen inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of achaogen incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the achaogen incs pipeline products reasons to buy evaluate achaogen incs strategic position with total access to detailed information on its product pipeline assess the growth potential of achaogen inc in its therapy areas of focus identify new drug targets and therapeutic classes in the achaogen incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of achaogen inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of achaogen inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of achaogen inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures achaogen inc snapshot achaogen inc overview key information key facts achaogen inc  research and development overview key therapeutic areas achaogen inc  pipeline review pipeline products by stage of development pipeline products  monotherapy achaogen inc  pipeline products glance achaogen inc  late stage pipeline products phase iii productscombination treatment modalities achaogen inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities achaogen inc  drug profiles plazomicin sulfate product description mechanism of action rd progress monoclonal antibodies for gramnegative bacterial infections product description mechanism of action rd progress small molecules to inhibit lpxc for gramnegative bacterial infections product description mechanism of action rd progress achn prodrug product description mechanism of action rd progress small molecules to inhibit metabolic enzymes for gramnegative bacterial infections product description mechanism of action rd progress achaogen inc  pipeline analysis achaogen inc  pipeline products by target achaogen inc  pipeline products by route of administration achaogen inc  pipeline products by molecule type achaogen inc  pipeline products by mechanism of action achaogen inc  recent pipeline updates achaogen inc  dormant projects achaogen inc  discontinued pipeline products discontinued pipeline product profiles achn achaogen inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables achaogen inc key information achaogen inc key facts achaogen inc  pipeline by indication  achaogen inc  pipeline by stage of development  achaogen inc  monotherapy products in pipeline  achaogen inc  phase iii  achaogen inc  preclinical  achaogen inc  discovery  achaogen inc  pipeline by target  achaogen inc  pipeline by route of administration  achaogen inc  pipeline by molecule type  achaogen inc  pipeline products by mechanism of action  achaogen inc  recent pipeline updates  achaogen inc  dormant developmental projects achaogen inc  discontinued pipeline products  list of figures achaogen inc  pipeline by top  indication  achaogen inc  pipeline by stage of development  achaogen inc  monotherapy products in pipeline  achaogen inc  pipeline by top  target  achaogen inc  pipeline by top  route of administration  achaogen inc  pipeline by top  molecule type  achaogen inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved achaogen inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports achaogen inc  product pipeline review   achaogen inc  product pipeline review   wgr  september  global  pages global markets direct description table of content sample report enquiry before buy related reports achaogen inc  product pipeline review  summaryglobal markets direct’s ‘achaogen inc  product pipeline review  ’ provides an overview of the achaogen inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of achaogen inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of achaogen inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of achaogen inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the achaogen inc’s pipeline productsreasons to buy evaluate achaogen inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of achaogen inc in its therapy areas of focus identify new drug targets and therapeutic classes in the achaogen inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of achaogen inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of achaogen inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of achaogen inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures achaogen inc snapshot achaogen inc overview key information key facts achaogen inc  research and development overview key therapeutic areas achaogen inc  pipeline review pipeline products by stage of development pipeline products  monotherapy achaogen inc  pipeline products glance achaogen inc  late stage pipeline products phase iii productscombination treatment modalities achaogen inc  clinical stage pipeline products phase ii productscombination treatment modalities achaogen inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities achaogen inc  drug profiles plazomicin product description mechanism of action rd progress monoclonal antibodies for pseudomonas aeruginosa infections product description mechanism of action rd progress small molecule inhibiting lpxc for pseudomonas aeruginosa infections product description mechanism of action rd progress small molecules for bacterial infections product description mechanism of action rd progress small molecules for gramnegative bacterial infections product description mechanism of action rd progress small molecules to inhibit metabolic enzymes for gramnegative bacterial infections product description mechanism of action rd progress achaogen inc  pipeline analysis achaogen inc  pipeline products by target achaogen inc  pipeline products by route of administration achaogen inc  pipeline products by molecule type achaogen inc  pipeline products by mechanism of action achaogen inc  recent pipeline updates achaogen inc  dormant projects achaogen inc  discontinued pipeline products discontinued pipeline product profiles achn achaogen inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesachaogen inc key information achaogen inc key facts achaogen inc  pipeline by indication  achaogen inc  pipeline by stage of development  achaogen inc  monotherapy products in pipeline  achaogen inc  phase iii  achaogen inc  phase ii  achaogen inc  preclinical  achaogen inc  discovery  achaogen inc  pipeline by target  achaogen inc  pipeline by route of administration  achaogen inc  pipeline by molecule type  achaogen inc  pipeline products by mechanism of action  achaogen inc  recent pipeline updates  achaogen inc  dormant developmental projects achaogen inc  discontinued pipeline products  list of figuresachaogen inc  pipeline by top  indication  achaogen inc  pipeline by stage of development  achaogen inc  monotherapy products in pipeline  achaogen inc  pipeline by top  target  achaogen inc  pipeline by top  route of administration  achaogen inc  pipeline by top  molecule type   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send achaogen inc  akao  stock price today  zacks quote overview stock activity open  day low  day high   wk low   wk high  avg volume  market cap  m dividend    beta  key earnings data earnings esp  most accurate est  current qtr est  current yr est  exp earnings date  prior year eps  exp eps growth yrna forward pe na peg ratio na medical » medical  drugs zacks earnings esp expected surprise prediction looks to find earnings surprises by focusing on the most recent analyst revisions this is done because generally speaking if an analyst reevaluates their earnings estimate right before an earnings release it means that they have fresh information which could potentially be more accurate than what analysts thought about a company two or three months ago the crux of this approach is comparing the most accurate estimate to the zacks consensus estimate although the zacks rank is also an important feature of the esp metric combining these two can help investors find stocks that are ready to beat the consensus at their next report and hopefully surge higher in price too in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time and best of all by using these parameters investors have seen  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings research report for akao all zacks’ analyst reports premium research for akao zacks rank hold  zacks industry rank top  out of  zacks sector rank bottom   out of  style scores f value  c growth  c momentum  d vgm earnings esp  research report for akao snapshot this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to get access to the zacks rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports zacks earnings esp expected surprise prediction looks to find earnings surprises by focusing on the most recent analyst revisions this is done because generally speaking if an analyst reevaluates their earnings estimate right before an earnings release it means that they have fresh information which could potentially be more accurate than what analysts thought about a company two or three months ago the crux of this approach is comparing the most accurate estimate to the zacks consensus estimate although the zacks rank is also an important feature of the esp metric combining these two can help investors find stocks that are ready to beat the consensus at their next report and hopefully surge higher in price too in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time and best of all by using these parameters investors have seen  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the three scores are based on the trading styles of growth value and momentum growth score a value score a momentum score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b zacks style scores education  learn more about the zacks style scores the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports   change in last  days view all zacks rank  strong buys premium research industry analysis top peers symbol zacks rank achaogen inc akao aerie pharmaceuticals inc aeri chemocentryx inc ccxi consort medical plc sponsored adr csrmy ionis pharmaceuticals inc ions recordati industria chimica e farmaceutica spa rcdtf summit therapeutics plc smmt see all medical  drugs peers zacks news for akao achaogens plazomicin gets breakthrough therapy designation am est zacks fogo de chao fogo to report q earnings whats in store am est zacks akao what are zacks experts saying now zacks private portfolio services achaogen akao shares march higher can it continue am est zacks  drug stocks poised to beat earnings estimates in q am est zacks achaogen akao shares march higher can it continue am est zacks company summary achaogen inc is a clinicalstage biopharmaceutical company it is focused on the discovery development and commercialization of novel antibacterials to treat multidrug resistant or mdr gramnegative infections the company is developing plazomicin its lead product candidate for the treatment of serious bacterial infections due to mdr enterobacteriaceae including carbapenemresistant enterobacteriaceae achaogen inc is headquartered in south san francisco california investor overview  achaogen investor overview investor relations investor overview press releases events  presentations corporate governance management board of directors committee composition financials  filings sec filings quarterly results stock information analyst coverage contact us shareholder tools briefcase email alerts snapshot print achaogen is a clinicalstage biopharmaceutical company passionately committed to the discovery development and commercialization of novel antibacterials to treat multidrug resistant or mdr gramnegative infections we are developing plazomicin our lead product candidate for the treatment of serious bacterial infections due to mdr enterobacteriaceae including carbapenemresistant enterobacteriaceae or cre in  the centers for disease control and prevention identified cre as a “nightmare bacteria” and an immediate public health threat that requires “urgent and aggressive action” in addition to plazomicin our research and development pipeline includes two programs that specifically target infections caused by pseudomonas aeruginosa which we refer to as our antipseudomonal programs we are also pursuing small molecule research programs targeting other essential gramnegative enzymes nasdaq akao      pm et on jul   delayed at least  minutes intra  mo  mo  yr press releases  archive jul   achaogen appoints dr karen bernstein to its board of directors jun   achaogen announces new employment inducement grants view all press releases  archive » events  presentations may   at  pm et first quarter  earnings call apr   at  am et th annual needham healthcare conference view all events  presentations »  achaogen inc present all rights reserved     privacy policy  terms of use akaonasdaq gm stock quote  achaogen inc  bloomberg markets error could not add to watchlist x  watchlist achaogen inc akaous nasdaq gm usd   as of  pm edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap m usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases  top  pharmaceutical stocks for   investopedia  top  pharmaceutical stocks for   investopedia there are currently no news stories for this ticker please check back later  achaogen appoints dr karen bernstein to its board of directors  cystic fibrosis therapeutics pipeline h  research report available at rnr market research  achaogen announces new employment inducement grants  achaogen highlights data demonstrating potential of plazomicin against mdr gramnegative bacteria at asm microbe  annual me  achaogen initiates cscape clinical development program with phase  study of orallyadministered antibacterial candidate  achaogen announces closing of public offering  achaogen announces multiple plazomicin presentations at asm microbe  annual meeting  achaogen announces pricing of public offering of common stock  plazomicin granted fda breakthrough therapy designation  achaogen announces proposed public offering of common stock there are currently no press releases for this ticker please check back later profile achaogen inc provides biopharmaceutical products the company discovers develops and commercializes antibacterials to treat multidrug resistant and gramnegative infections achaogen serves customers in the united states address  shoreline courtsuite south san francisco ca united states phone  website wwwachaogencom executives board members kenneth j hillan chief executive officer blake wise presidentcoo tobin schilke chief financial officer janet dorling chief commercial officer lee swem chief scientific officer show more achaogen inc private company information  bloomberg july    am et biotechnology company overview of achaogen inc snapshot people company overview achaogen inc a latestage biopharmaceutical company discovers develops and commercializes antibacterials to treat multidrug resistant mdr gramnegative infections in the united states the company is principally developing plazomicin which is in phase iii clinical trial for the treatment of serious bacterial infections including urinary tract infections blood stream infections and other infections due to mdr enterobacteriaceae comprising carbapenemresistant enterobacteriaceae it is also involved in the research and development of antipseudomonal lpxc inhibitor compounds for the treatment of bacterial infections and therapeutic antibody discovery program the company has licen achaogen inc a latestage biopharmaceutical company discovers develops and commercializes antibacterials to treat multidrug resistant mdr gramnegative infections in the united states the company is principally developing plazomicin which is in phase iii clinical trial for the treatment of serious bacterial infections including urinary tract infections blood stream infections and other infections due to mdr enterobacteriaceae comprising carbapenemresistant enterobacteriaceae it is also involved in the research and development of antipseudomonal lpxc inhibitor compounds for the treatment of bacterial infections and therapeutic antibody discovery program the company has license and collaboration agreements with thermo fisher scientific inc to develop and commercialize an assay to to enable patients to receive safe and efficacious doses of plazomicin crystal biosciences inc to discover monoclonal antibodies against multiple targets ionis pharmaceuticals inc for certain patents relating to aminoglycoside antibacterial compounds and related knowhow to develop and commercialize certain novel aminoglycoside antibacterial compounds and hovione limited to manufacture the active pharmaceutical ingredient for plazomicin the company was incorporated in  and is based in south san francisco california detailed description  shoreline courtsuite south san francisco ca united statesfounded in  employees phone  wwwachaogencom key executives for achaogen inc dr kenneth j hillan mb chb chief executive officer and director age  total annual compensation k mr blake wise president and chief operating officer age  total annual compensation k compensation as of fiscal year  achaogen inc key developments achaogen inc announces board changes jul   on july   alan b colowick phd submitted his resignation as an independent director of the board of directors of achaogen inc and as a member of the audit committee and the compensation committee of the board effective at the close of business on july   dr colowick is planning to focus on his new role as a partner at sofinnova ventures on july   the board appointed karen bernstein phd effective immediately to serve as a member of the board dr bernstein was appointed as a class i director with an initial term expiring at the companys  annual meeting of stockholders filling a vacancy dr bernstein was also elected to serve as a member of the nominating and corporate governance committee of the board the board has determined that dr bernstein is independent as defined in listing rule  of the nasdaq stock market llc for purposes of serving on the nominating committee achaogen inc announces board changes jul   achaogen inc has announced the appointment of dr karen bernstein cofounder and chairman of biocentury inc to its board of directors dr bernstein brings to achaogen significant leadership and three decades of experience writing and publishing on biotechnology developments in addition the company announced that effective july   alan colowick md mph will step down as a board member of the company to focus on his new role as a partner at sofinnova ventures dr bernstein is currently the chairman of biocentury inc which she cofounded and for which she was chairman and editorinchief from  to  achaogen inc presents at bio international conference  jun  am may   achaogen inc presents at bio international conference  jun  am venue san diego convention center san diego ca  united states speakers blake wise president and chief operating officer similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target private placement may    request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states bertelsmann ag europe the advertising council inc united states rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact achaogen inc please visit wwwachaogencom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close achaogen inc  product pipeline review   purchase this report achaogen inc  product pipeline review   published pages publisher report code sep   global markets direct asdr published sep      pages       publisher  global markets direct     report code  asdr descriptiondesc contentcont figures  tablesfiguresfig free samplesample achaogen inc  product pipeline review  summarythe new report achaogen inc  product pipeline review  ’ provides an overview of the achaogen inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of achaogen inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsthe new report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from the new report proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by the new report team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of achaogen inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of achaogen inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the achaogen inc’s pipeline productsreasons to buy evaluate achaogen inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of achaogen inc in its therapy areas of focus identify new drug targets and therapeutic classes in the achaogen inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of achaogen inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of achaogen inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of achaogen inc and identify potential opportunities in those areas avoid intellectual property rights related issues purchase this report us  euro € gbp £ user pdf us  site pdf us  enterprise pdf us  add to cart   lowest price guarantee license and delivery order process  question about this report this report can be of interest as well free fatty acid receptor  g protein coupled receptor  or g protein coupled receptor  or g protein coupled recept published june   report code asdr mark your calendar nd drug development forum  september   september boston united states microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft achaogen akao  stock predictions  price targets facebook autocomplete demo post a rating  month price target   home trending sign up log in achaogen inc akao median target price   upside positive ratings  of  analysts latest  hc wainwright  buy     view all analyst ratings for akao » facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » achaogen home deep experience in antibacterial drug development passionately committed to the discovery development and commercialization of innovative antibacterials to treat multidrug resistant mdr gramnegative infectionspipelinewe are a latestage biopharmaceutical company committed to treating serious infections learn more about our pipelinesciencewe are focused on the discovery and development of antibiotics to treat gramnegative infections and have developed proprietary knowhow through our work on multiple antibiotic classes learn more about our science news  achaogen inc present all rights reserved     privacy policy  terms of use bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one